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• A novel coronavirus that manifested in 2019 (SARS-CoV-2) has led to a pandemic of pneumonia-
related illness (COVID-19). There is an urgent need to better understand risk factors for contracting 
the infection and for poorer prognosis thereafter.  
• Evidence is emerging that COVID-19 disproportionately affects black and minority ethnic 
individuals, but the underlying mechanism is unknown. One potential mediator could be their higher 
prevalence of apparent vitamin D deficiency.  
• We explored whether blood 25 hydroxyvitamin D (25(OH)D) concentration was associated with 
COVID-19 risk among UK Biobank participants, and whether this explained wholly, or in part, the 
higher incidence of COVID-19 infection in ethnic minority participants. 
• Our analyses of UK Biobank data provided no evidence to support a potential role for (25(OH)D) 
concentration to explain susceptibility to COVID-19 infection either overall or in explaining 





Background and Aims 
COVID-19 and low levels of vitamin D appear to disproportionately affect black and 
minority ethnic individuals. We aimed to establish whether blood 25-hydroxyvitamin D 
(25(OH)D) concentration was associated with COVID-19 risk, and whether it explained the 
higher incidence of COVID-19 in black and South Asian people. 
Methods 
UK Biobank recruited 502,624 participants aged 37-73 years between 2006 and 2010. 
Baseline exposure data, including 25(OH)D concentration and ethnicity, were linked to 
COVID-19 test results. Univariable and multivariable logistic regression analyses were 
performed for the association between 25(OH)D and confirmed COVID-19, and the 
association between ethnicity and both 25(OH)D and COVID-19. 
Results 
Complete data were available for 348,598 UK Biobank participants. Of these, 449 had 
confirmed COVID-19 infection. Vitamin D was associated with COVID-19 infection 
univariably (OR=0.99; 95% CI 0.99 – 0.999; p=0.013), but not after adjustment for 
confounders (OR=1.00; 95% CI=0.998-1.01; p=0.208). Ethnicity was associated with 
COVID-19 infection univariably (blacks versus whites OR=5.32, 95% CI=3.68 – 7.70, p-
value<0.001; South Asians versus whites OR=2.65, 95% CI=1.65 – 4.25, p-value<0.001).  
Adjustment for 25(OH)D concentration made little difference to the magnitude of the 
association.  
Conclusions 
Our findings do not support a potential link between vitamin D concentrations and risk of 
































A novel coronavirus that manifested in 2019 (SARS-CoV-2) has led to a pandemic of 
pneumonia-related illness (COVID-19) with an estimated case fatality of around 1%.  There 
is an urgent need to better understand risk factors for contracting the infection and for poorer 
prognosis thereafter.  
 
There is growing evidence that COVID-19 disproportionately affects black and minority 
ethnic individuals, with the Intensive Care National Audit and Research Centre reporting that 
a third of confirmed cases admitted to critical care in England are non-white1. This compares 
with the 2011 Census figures which show that 14% of  the general population of England and 
Wales identify themselves as black and minority ethnic individuals.2 Similarly, in the United 
States a pattern of higher risk has been observed in African Americans. 3 Consequently, the 
relationship between ethnicity and COVID-19 has been identified as an urgent public health 
research priority. 4 
 
Several factors have been proposed to explain the apparent greater risk of COVID-19 
infection in ethnic minority groups.  UK Government statistics show that people from black 
and minority ethnic backgrounds are more likely than white British people to live in the most 
socioeconomically deprived areas of England.5  Furthermore, certain minority ethnic groups 
experience a higher burden of comorbid disease, 6 which may put them at higher risk of more 
severe COVID-19 infection. 7, 8 
 
One potential mediator could be the higher prevalence of apparent vitamin D deficiency in 
black and minority ethnic  populations.4  Vitamin D is variably inversely associated with 
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multiple health outcomes and mortality (although these associations may not be causal).9 
Most vitamin D results from production in the skin following exposure to ultraviolet (UV) 
radiation from the sun. Individuals with dark skin have, on average, lower concentrations of 
blood vitamin D because the melanin in dark skin does not absorb as much UV. 10 
Furthermore, deficiency is more common in high latitude countries such as the UK.  Whilst 
most chronic conditions have not been improved by vitamin D supplementation, a recent 
meta-analysis of randomised trials suggested vitamin D may lessen the risk of acute 
respiratory infections.11  
 
In this study, we hypothesised that blood 25 hydroxyvitamin D (25(OH)D) concentration was 
associated with COVID-19 risk among UK Biobank participants, and explained wholly, or in 
part, the higher incidence of COVID-19 infection in ethnic minority participants.  
 
Subjects 
UK Biobank recruited 502,624 participants aged 37-73 years across England, Scotland and 
Wales between 2006 and 2010. Its aim was to identify the causes of disease and death in 
middle and old age by following up participants over time. At baseline, biological 
measurements were recorded and touch-screen questionnaires administered according to a 
standardised protocol.12, 13 The study received ethical approval from the North West Multi-
Centre Research Ethics Committee (REC reference: 16/NW/0274), and was conducted in 
accord with the principles of the Declaration of Helsinki. All participants gave written 






Materials and Methods 
Baseline data from UK Biobank were linked to COVID-19 test results provided by Public 
Health England,14 including the specimen date, origin (whether the person was an inpatient or 
not) and result (positive or negative). Confirmed COVID-19 infection was defined as at least 
one positive test result. Data were available for the period 16th March 2020 to 14th April 
2020. 
 
Exposures were measured at the baseline assessment visits conducted between 2006 and 
2010. Blood collection sampling procedures for the study have previously been described and 
validated.15 Biochemical assays, including 25(OH)D, a measure of vitamin D status, were 
performed at a central laboratory on around 480,000 samples. Further details of these 
measurements can be found in the UK Biobank Data Showcase and Protocol.16 Vitamin D 
was imputed with the minimum detectable value (10nmol/L) if it was below the limit of 
detection, and the maximum detectable value (375nmol/L) if too high for detection.  
 
Ethnicity was self-reported, and categorised as white, black, South Asian, or other. 
Smoking status was self-reported and categorised as current or non (ex/former) smoker. 
Blood pressure was measured at the baseline visit using an automated measurement, and the 
average of available measures used. Height was measured using a Seca 202 height measure. 
Weight was measured to the nearest 0.1 kg using the Tanita BC-418 MA body composition 
analyser. Body mass index (BMI) was derived from weight(kg)/height(m)2. It was 
categorised into underweight (BMI<18.5kg/m2), normal weight (BMI 18.5-24.9 kg/m2), 
overweight (BMI≥25-29.9 kg/m2) and obese (BMI≥30 kg/m2). Area-level socioeconomic 
deprivation was assessed by the Townsend score (incorporating measures of unemployment, 
non-car ownership, non-home ownership and household overcrowding).17 Higher scores on 
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the Townsend score represent greater socioeconomic deprivation; scores were categorised 
into quintiles. Diabetes at baseline was defined as self-reported physician-diagnosed type 1 or 
type 2 diabetes, a primary care or hospital record of diabetes at or before recruitment (defined 
as ICD-10 codes E10-E14.9), or diabetes medication. Household income was self-reported 
and categorised into: <£18,000; £18,000-£30,999; £31,000-£51,999; £52,000-£100,000; or 
>£100,000. Health was self-rated as excellent, good, fair, or poor. Long-standing illness, 
disability or infirmity was self-reported as yes or no.  
 
Univariable logistic regression analysis was performed of the association between 25(OH)D 
concentration (as a continuous variable) and confirmed COVID-19 infection. The model was 
then adjusted for sex, month of assessment, Townsend deprivation quintile, household 
income, self-reported health rating, smoking status, BMI quintile, ethnicity, age at 
assessment, diabetes, systolic blood pressure (SBP), diastolic blood pressure (DBP), and 
long-standing illness, disability or infirmity. As sensitivity analyses these models were 
repeated with participants categorised as vitamin D deficient (defined as <25nmol/L) or not 
deficient18 and then categorised as vitamin D insufficient (defined as <50nmol/L) or 
sufficient. 
 
Next, univariable logistic regression was performed of the association between ethnicity and 
confirmed COVID-19 infection. The model was first adjusted for 25(OH)D, then sex, month 
of assessment, Townsend deprivation quintile, household income, self-reported health rating, 
smoking status, BMI quintile, age at assessment, diabetes, SBP, DBP, and long-standing 
illness, disability or infirmity.  
Finally, multivariable analysis was performed including an ethnicity*vitamin D deficiency 




Results were available for 2,724 COVID-19 tests conducted on 1,474 individuals. Complete 
data on (25(OH)D) concentration and covariates were available for 348,598 UK Biobank 
participants. Of these, 449 had a positive COVID-19 test. 
 
Table 1 presents study participants by presence or absence of positive COVID-19 test result. 
Median 25(OH)D concentration measured at recruitment was lower in patients who 
subsequently had confirmed COVID-19 infection (28.7 (IQR 10.0-43.8) nmol/L) than other 
participants (32.7 (IQR 10.0-47.2) nmol/L). It predicted COVID-19 infection univariably 
(Table 2; OR=0.99, 95% CI 0.99 – 0.999, p=0.013), but not after adjustment for covariates 
(OR=1.00; 95% CI=0.998-1.01; p=0.208). Exposures that did predict COVID-19 status in the 
multivariable logistic regression were male sex (OR=1.41; 95% CI=1.16-1.71; p-
value=0.001), higher socioeconomic deprivation (highest vs lowest Townsend quintile 
OR=1.89; 95% CI=1.37-2.60; p-value<0.001), poorer self-reported health status ( poor health 
vs excellent health OR=2.32; 95% CI=1.45-3.72; p-value<0.001), age at assessment 
(OR=1.02; 95% CI=1.00-1.03; p-value=0.016), being overweight (OR=1.34; 95% CI=1.04-
1.72; p-value=0.024) or obese (OR=1.62; 95% CI=1.23-2.14; p-value=0.001), and non-white 
ethnicity (blacks OR=4.30, 95% CI=2.92-6.31, p-value<0.001; South Asians OR=2.42, 95% 
CI=1.50-3.93, p-value<0.001) (Figure 1). 
 
When participants were categorised into vitamin D deficient (<25nmol/L) and not deficient 
the pattern of results was similar to those observed with vitamin D concentration entered as a 
continuous variable (univariable OR=1.37, 95% CI=1.07-1.76, p-value=0.011; adjusted 
OR=0.92, 95% CI=0.71-1.21, p-value=0.564) (Table 2).  When participants were categorised 
into vitamin D insufficient (<50nmol/L) and sufficient there was no association with COVID-
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19 infection either univariably (OR=1.19, 95% CI=0.99-1.44, p-value=0.068), nor 
multivariably (OR=0.88, 95% CI=0.72-1.08, p-value=0.232) (Table 2). 
 
In the study, 331,849 (95.20%) participants were white, 5,054 (1.45%) black, 5,936 (1.70%) 
South Asian, and 5,759 (1.65%) other. Of the 449 participants with confirmed COVID-19 
infection, 385 (85.75%) were white, 32 (7.13%) black, 19 (4.23%) South Asian, and 13 
(2.90%) other. Median 25(OH)D concentration was 33.8 (IQR 10.0-48.1) nmol/L in white 
participants, 21.0 (IQR 10.0-29.9) in black participants, 14.5 (IQR 15.5-22.1) in South Asian 
participants, and 23.3 (IQR 10.0-33.7) nmol/L in others. In this study 38,778 (11.69%) white, 
1,834 (36.29%) black, 3,403 (57.33%) South Asian, and 1,671 (29.02%) of other participants 
were vitamin D deficient at baseline. 
 
In logistic regression, black ethnicity and South Asian ethnicity were both associated with 
confirmed COVID-19 infection univariably (OR=5.49, 95% CI=3.82 – 7.88, p-value<0.001; 
OR=2.76, 95% CI=1.74 – 4.39, p-value<0.001 respectively) compared with whites.  
Adjustment for 25(OH)D concentration made little difference to the magnitude of the 
associations (Table 3). Results were similar when, instead of adjusting for 25(OH)D 
concentration, adjustment was made separately for vitamin D deficiency and vitamin D 
insufficiency.  
 
There was no significant interaction between ethnicity and vitamin D deficiency (OR=0.90; 





Our findings are consistent with previous studies 7, 19  in demonstrating a higher risk of 
confirmed COVID-19 infection in ethnic minority groups. Vitamin D has been suggested as 
possibly protective of COVID-19 infection 20-22 and, if so, could plausibly play a role in 
ethnic variations in COVID-19 infection. However, we found no association between 
25(OH)D and COVID-19 infection after adjusting for potential confounders. Therefore, 
despite 25(OH)D concentration being lower in black and minority ethnic participants, there 
was no evidence that it might play a role in their higher risk of COVID-19 infection.  
 
It has been suggested in some media outlets that language barriers may contribute to ethnic 
differences in COVID-19 risk.  This is unlikely to contribute to the risk we observed in UK 
Biobank because all participants spoke English (albeit with the possibility of fluency 
variation).  The association with ethnicity was only slightly attenuated after adjustment for 
socioeconomic and lifestyle differences in white and black and minority ethnic participants; 
the risk of COVID-19 remained around 4-fold in black participants and more than 2-fold in 
South Asians. Further studies are required to determine the mechanisms underlying ethnic 
variations in risk of COVID-19 infection and its severity.  It may be that pathways related to 
cardiometabolic conditions or differences in cardiorespiratory reserve, or potentially other 
social factors, are more relevant, as we have recently discussed.23   
 
Our study replicated findings showing increased risk of COVID-19 in black and minority 
ethnic individuals, in men, and in people who are overweight or obese. It is surprising that we 
did not observe an association between diabetes or blood pressure and COVID-19 risk. Other 
studies have shown increased risk of hospitalisation and severe illness requiring ventilation in 
patients with diabetes and hypertension. 7, 24 However, ours is a relatively healthy general 
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population cohort. Furthermore, we do not have information on the severity of COVID-19 
and have included all positive tests rather than only severe cases.  
 
We did not show an independent association between smoking and COVID-19. Evidence 
from the literature is mixed.  Initial studies suggested that current smoking increases the risk 
of severe infection.25 However, this has since been disputed with some evidence that smoking 
may even protect against initial infection.26 
 
The strengths of UK Biobank include its extensive phenotyping which enables the adjustment 
for demographic and lifestyle risk factors, disease and ill health, its large sample size, and its 
central processing laboratory for biochemical assays. However, it is not representative of the 
general population, in that participants live in less socioeconomically deprived areas, are 
predominantly Caucasian, and have fewer self-reported health conditions. 27 We have 
demonstrated that ethnic differences in COVID-19 infection exist in this relatively healthy 
population. Baseline measurements, including 25(OH)D concentration and health status, were 
obtained a decade ago. It would be preferable to have measurements immediately preceding 
development of COVID-19. However, 25(OH)D concentrations vary more by season than 
year, and generally track over time. 28  
 
Our study is the first to assess whether there is an association between blood 25(OH)D 
concentration and COVID-19 risk. We found no such link, suggesting that measurement of 
25(OH)D would not be useful to assess risk in clinical practice. Furthermore, our results 
suggest that vitamin D is unlikely to be the underlying mechanism for the higher risk 
observed in black and minority ethnic individuals and vitamin D supplements are unlikely to 




Our analyses of UK Biobank data provided no evidence to support a potential role for 
(25(OH)D) concentration to explain susceptibility to COVID-19 infection either overall or in 
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Table 1: Characteristics of study population by presence or absence of confirmed COVID-19 
infection 
 No COVID-19 COVID-19  
N (%) N (%) P value 
Sex Male 168,391 (48.37) 265 (59.02)  
<0.001 Female 179,758 (51.63) 184 (40.98) 




Black 5,022 (1.44) 32 (7.13) 
South Asian 5,917 (1.70) 19 (4.23) 
Other 5,746 (1.65) 13 (2.90) 
Current smoking 
status 
Yes 312,037 (89.63) 398 (88.64)  
0.493 No 36,112 (10.37) 51 (11.36) 
Townsend deprivation 
quintile 





2 70,726 (20.31) 76 (16.93) 
3 70,644 (20.29) 64 (14.25) 
4 70,270 (20.18) 105 (23.39) 
5 65,840 (18.91) 143 (31.85) 




Normal weight 115,410 (33.15) 95 (21.16) 
Overweight 148,210 (42.57) 194 (43.21) 
Obese 82,770 (23.77) 158 (35.19) 
Self-reported health 
rating 




Good 203,640 (58.49) 227 (50.56) 
Fair 69,676 (20.01) 133 (29.62) 
Poor 14,325 (4.11) 44 (9.80) 
Long-standing illness, 
disability or infirmity 
Yes 237,470 (68.21) 245 (54.57)  
<0.001 No 110,679 (31.79) 204 (45.43) 
Diabetes Yes 329,324 (94.59) 400 (89.09)  
<0.001 No 18,825 (5.41) 49 (10.91) 
     
  Median (IQR) Median (IQR)  
Vitamin D  32.7 (10.0-47.2) 28.7 (10.0-43.8) <0.01 
Age at assessment  49 (38-57) 49 (40-58) <0.05 
SBP  138 (125-151) 138 (127-153) 0.177 
DBP  82 (75-89) 83 (76-90) <0.01 
Categorical variables compared by chi2 test; continuous variables compared by Mann-
Whitney U test 
N number; BMI body mass index; IQR inter-quartile range; SBP systolic blood pressure; 






Table 2: Association between Vitamin D and confirmed COVID-19 infection 
 Univariable Multivariable* 
 OR (95% CI) p-value OR (95% CI) p-value 
Vitamin D (nmol/L) 0.99 (0.99 – 0.999) 0.013 1.00 (0.998 – 1.01) 0.208 
Vitamin D deficient (<25nmol/L) 1.37 (1.07 – 1.76) 0.011 0.92 (0.71 – 1.21) 0.564 
Vitamin D insufficient (<50nmol/L) 1.19 (0.99 – 1.44) 0.068 0.88 (0.72 – 1.08) 0.232 
     
OR odds ratio; CI confidence interval 
*adjusted for ethnicity, sex, month of assessment, Townsend deprivation quintile, household income, self-reported health rating, smoking status, 




Table 3: Association between ethnicity and confirmed COVID-19 infection 
 Univariable Adjusted for Vitamin D 
concentration 
Multivariable* 
 OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value 
White (referent) 1  1  1  
Black 5.49 (3.82 – 7.88) <0.001 5.32 (3.68 – 7.70) <0.001 4.30 (2.92 – 6.31) <0.001 
South Asian 2.76 (1.74 – 4.39) <0.001 2.65 (1.65 – 4.25) <0.001 2.42 (1.50 – 3.93) <0.001 
Other 1.95 (1.12 – 3.39) 0.018 1.90 (1.09 – 3.32) 0.024 1.87 (1.07 – 3.28) 0.029 
OR odds ratio; CI confidence interval 
*also adjusted for sex, month of assessment, Townsend deprivation quintile, household income, self-reported health rating, smoking status, BMI 
category, age at assessment, diabetes, SBP, DBP, and long-standing illness, disability or infirmity 
